Candidate oncogenic drivers affecting MAPK signaling were identified either as mutations of Kras, Nf1 and Hippo effectors (Fat1/4), or as amplification of Kras and Myc in p53 deficient mice, or Met and Yap1 in radiation-induced STS. Here, KRAS is linked to telomere syndrome.